Personensuche
X
?
1
Crude SARS-CoV-2 seroprevalence profile by months and healt..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s003. , 2024
doi:10.1371/journal.pgph.0002380.s003. , 2024
?
2
Crude SARS-CoV-2 seroprevalence profile by clinical symptom:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s004. , 2024
doi:10.1371/journal.pgph.0002380.s004. , 2024
?
3
Flow diagram of the study:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g001. , 2024
doi:10.1371/journal.pgph.0002380.g001. , 2024
?
4
Testing SARS-CoV-2 immune response parameters (IgM, IgG, CD..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s002. , 2024
doi:10.1371/journal.pgph.0002380.s002. , 2024
?
5
Overall variation of CD4+ (A, D), IFN-γ (B, E) and IL-6 (C,..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g005. , 2024
doi:10.1371/journal.pgph.0002380.g005. , 2024
?
6
Clinical value of symptoms for prognostic of IgM seropositi..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s005. , 2024
doi:10.1371/journal.pgph.0002380.s005. , 2024
?
7
Fig 2 -:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g002. , 2024
doi:10.1371/journal.pgph.0002380.g002. , 2024
?
8
Univariate logistic regression between SARS-CoV-2 antibodie..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t002. , 2024
doi:10.1371/journal.pgph.0002380.t002. , 2024
?
9
Predictors of the presence of anti-SARS-CoV-2 antibodies am..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t004. , 2024
doi:10.1371/journal.pgph.0002380.t004. , 2024
?
10
Crude prevalence of SARS–CoV–2 antibodies by study sites:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g003. , 2024
doi:10.1371/journal.pgph.0002380.g003. , 2024
?
11
Univariate logistic regression between SARS-CoV-2 antibodie..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t002. , 2024
doi:10.1371/journal.pgph.0002380.t002. , 2024
?
12
Predictors of the presence of anti-SARS-CoV-2 antibodies am..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.t004. , 2024
doi:10.1371/journal.pgph.0002380.t004. , 2024
?
13
Clinical value of symptoms for prognostic of IgM seropositi..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s005. , 2024
doi:10.1371/journal.pgph.0002380.s005. , 2024
?
14
Variation of CD4+, INF-γ and IL-6 by seropositivity status,..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.g006. , 2024
doi:10.1371/journal.pgph.0002380.g006. , 2024
?
15
Ethical clearance of the study: English translation and ori..:
Arlette Flore Moguem Soubgui ; Wilfred Steve Ndeme Mboussi ; Loick Pradel Kojom Foko..
doi:10.1371/journal.pgph.0002380.s001. , 2024
doi:10.1371/journal.pgph.0002380.s001. , 2024